4.74
price up icon1.28%   0.06
 
loading
Nuvation Bio Inc stock is traded at $4.74, with a volume of 1.97M. It is up +1.28% in the last 24 hours and down -18.28% over the past month. Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
See More
Previous Close:
$4.68
Open:
$4.74
24h Volume:
1.97M
Relative Volume:
0.29
Market Cap:
$1.66B
Revenue:
$143.05M
Net Income/Loss:
$-145.99M
P/E Ratio:
-11.07
EPS:
-0.4282
Net Cash Flow:
$-134.06M
1W Performance:
-4.24%
1M Performance:
-18.28%
6M Performance:
-1.66%
1Y Performance:
+25.73%
1-Day Range:
Value
$4.67
$4.855
1-Week Range:
Value
$4.61
$5.06
52-Week Range:
Value
$3.36
$9.75

Nuvation Bio Inc Stock (NUVB) Company Profile

Name
Name
Nuvation Bio Inc
Name
Phone
332-208-6102
Name
Address
1500 BROADWAY, NEW YORK
Name
Employee
298
Name
Twitter
Name
Next Earnings Date
2026-11-02
Name
Latest SEC Filings
Name
NUVB's Discussions on Twitter

Compare NUVB vs VRTX, MRNA, REGN, ARGX, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
NUVB icon
NUVB
Nuvation Bio Inc
4.74 1.66B 143.05M -145.99M -134.06M -0.4282
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
509.74 129.20B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
238.40 95.18B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
801.26 82.49B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
849.01 53.39B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
371.37 42.01B 5.76B 514.49M 1.10B 4.4813

Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-30-26 Initiated Citigroup Buy
Aug-21-26 Initiated Cantor Fitzgerald Overweight
Aug-18-26 Initiated JP Morgan Overweight
Nov-24-25 Initiated Truist Buy
Nov-19-25 Initiated B. Riley Securities Buy
Sep-30-25 Initiated Jefferies Buy
Apr-23-25 Initiated Citizens JMP Mkt Outperform
Mar-27-24 Upgrade Jefferies Hold → Buy
Mar-26-24 Upgrade BTIG Research Neutral → Buy
Jan-06-23 Downgrade Jefferies Buy → Hold
Aug-02-22 Downgrade BMO Capital Markets Outperform → Market Perform
Aug-02-22 Downgrade BTIG Research Buy → Neutral
May-04-22 Initiated H.C. Wainwright Buy
Oct-15-21 Resumed BTIG Research Buy
Apr-06-21 Initiated RBC Capital Mkts Outperform
Mar-08-21 Initiated BMO Capital Markets Outperform
Mar-08-21 Initiated BTIG Research Buy
Mar-08-21 Initiated Cowen Outperform
Mar-08-21 Initiated Jefferies Buy
Mar-08-21 Initiated Wedbush Outperform
View All

Nuvation Bio Inc Stock (NUVB) Latest News

pulisher
Oct 12, 2026

3 Promising Penny Stocks With Market Caps Over $200M - Simply Wall Street

Oct 12, 2026
pulisher
Oct 11, 2026

Nuvation Bio Inc. (NUVB) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 11, 2026
pulisher
Oct 10, 2026

Nuvation Bio Inc. (NUVB) stock price, news, quote and history - Yahoo Finance Singapore

Oct 10, 2026
pulisher
Oct 03, 2026

Nuvation Bio Inc. (NUVB) stock price, news, quote and history - Yahoo Finance UK

Oct 03, 2026
pulisher
Oct 01, 2026

What Makes Nuvation Bio (NASDAQ:NUVB) Stand Out in Nasdaq Biotech? - Kalkine Media

Oct 01, 2026
pulisher
Oct 01, 2026

Elite Penny Stocks To Watch In October 2026 - Simply Wall Street

Oct 01, 2026
pulisher
Sep 30, 2026

Citigroup Initiates Nuvation Bio at Buy With $12 Price Target - Moomoo

Sep 30, 2026
pulisher
Sep 30, 2026

Nuvation stock, Jazz stock gain new Buys at Citi (NUVB:NYSE) - Seeking Alpha

Sep 30, 2026
pulisher
Sep 30, 2026

Citigroup Initiates Nuvation Bio at Buy With $12 Price Target - Yahoo Finance

Sep 30, 2026
pulisher
Sep 18, 2026

Nuvation Bio Inc. (NUVB): Investor Outlook With A 115.82% Potential Upside - DirectorsTalk Interviews

Sep 18, 2026
pulisher
Sep 17, 2026

Why Is Nuvation Bio Stock Gaining Thursday? - Benzinga

Sep 17, 2026
pulisher
Sep 17, 2026

Nuvation Bio stock gains on FDA label update for IBTROZI - Investing.com

Sep 17, 2026
pulisher
Sep 17, 2026

Nuvation Bio Inc. (NUVB) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore

Sep 17, 2026
pulisher
Sep 17, 2026

Nuvation Bio stock rises on Ibtrozi label update (NUVB:NYSE) - Seeking Alpha

Sep 17, 2026
pulisher
Sep 17, 2026

Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer - PR Newswire

Sep 17, 2026
pulisher
Sep 17, 2026

Nuvation Bio Inc. (NYSE:NUVB) Wins FDA OK To Add ~50-Month DOR To IBTROZI Label - TradingView

Sep 17, 2026
pulisher
Sep 16, 2026

Nuvation Bio (NUVB) Reports IBTROZI Efficacy Across ROS1 Lung Cancer Subgroups - Yahoo Finance

Sep 16, 2026
pulisher
Sep 15, 2026

Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer - PR Newswire

Sep 15, 2026
pulisher
Sep 11, 2026

Nuvation Bio (NUVB) Stock Looks Stretched Despite Its 354% Three Year Run - webull.com

Sep 11, 2026
pulisher
Sep 10, 2026

NUVB: IBTROZI dominates ROS1 with best-in-class efficacy, while safusidenib advances across glioma subtypes - TradingView

Sep 10, 2026
pulisher
Sep 10, 2026

Nuvation Bio at 12th Annual Cantor Fitzgerald Global Healthcare Conference: pipeline gains - Investing.com

Sep 10, 2026
pulisher
Sep 10, 2026

NUVB: IBTROZI’s superior efficacy and safety drive rapid market share gains, with a strong pipeline advancing - TradingView

Sep 10, 2026
pulisher
Sep 10, 2026

Nuvation Bio at 12th Annual Cantor Fitzgerald Global Healthcare Conference: pipeline gains - Investing.com Canada

Sep 10, 2026
pulisher
Sep 09, 2026

Nuvation Bio at citigroup biopharma summit: growth rests on three pillars - Investing.com Canada

Sep 09, 2026
pulisher
Sep 09, 2026

Nuvation Bio at citigroup biopharma summit: growth rests on three pillars - Investing.com UK

Sep 09, 2026
pulisher
Sep 09, 2026

NUVB: IBTROZI and safusidenib drive growth with best-in-class efficacy and expanding global opportunities - TradingView

Sep 09, 2026
pulisher
Sep 09, 2026

NUVB: IBTROZI and safusidenib drive strong growth, with major clinical and commercial milestones ahead - TradingView

Sep 09, 2026
pulisher
Sep 06, 2026

Jim Cramer sends strong 5-word message on surging biotech stock - Yahoo Finance

Sep 06, 2026
pulisher
Sep 06, 2026

Jim Cramer sends strong 5-word message on surging biotech stock - thestreet.com

Sep 06, 2026
pulisher
Sep 04, 2026

Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is... - Benzinga

Sep 04, 2026
pulisher
Sep 03, 2026

Cramer's lightning round: Nuvation Bio 'is a pure spec' - CNBC

Sep 03, 2026
pulisher
Sep 03, 2026

Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect? - Yahoo Finance

Sep 03, 2026
pulisher
Sep 03, 2026

Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect? - Zacks Investment Research

Sep 03, 2026
pulisher
Sep 02, 2026

Nuvation Bio to Participate in Upcoming Investor Conferences - Investing News Network

Sep 02, 2026
pulisher
Sep 02, 2026

Nuvation Bio to Participate in Upcoming Investor Conferences - PR Newswire

Sep 02, 2026
pulisher
Aug 31, 2026

Nuvation Bio (NUVB) Upgraded to Buy: Here's Why - Yahoo Finance

Aug 31, 2026
pulisher
Aug 26, 2026

Nuvation Bio downgraded to Hold after 200% rall... - Pluang

Aug 26, 2026
pulisher
Aug 26, 2026

NUVB|Nuvation Bio Inc|Price:7.100|Chg%:+0.340 - TradingKey

Aug 26, 2026
pulisher
Aug 22, 2026

Nuvation Bio | 4: Statement of changes in beneficial ownership of securities-Officer Hattersley Gary - Moomoo

Aug 22, 2026
pulisher
Aug 21, 2026

Nuvation Bio (NUVB) CSO sells 100K shares at $7.09 - Stock Titan

Aug 21, 2026
pulisher
Aug 21, 2026

Why is Nuvation Bio stock rallying today? By Investing.com - Investing.com Canada

Aug 21, 2026
pulisher
Aug 21, 2026

Why is Nuvation Bio stock rallying today? By Investing.com - Investing.com UK

Aug 21, 2026
pulisher
Aug 21, 2026

Nuvation Bio stock rises after Cantor starts at Overweight - Investing.com

Aug 21, 2026
pulisher
Aug 21, 2026

Nuvation Bio rises as Cantor initiates at overweight - Seeking Alpha

Aug 21, 2026
pulisher
Aug 21, 2026

Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating - Investing.com

Aug 21, 2026
pulisher
Aug 21, 2026

Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating By Investing.com - Investing.com Canada

Aug 21, 2026
pulisher
Aug 21, 2026

Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating By Investing.com - Investing.com India

Aug 21, 2026
pulisher
Aug 21, 2026

Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating - Investing.com

Aug 21, 2026
pulisher
Aug 20, 2026

JPMorgan sees 100% upside in overlooked cancer drug stock - thestreet.com

Aug 20, 2026
pulisher
Aug 20, 2026

FDA grants Nuvation fast-track status for safusidenib in IDH1-mutant glioma - AllSci

Aug 20, 2026

Nuvation Bio Inc Stock (NUVB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Nuvation Bio Inc Stock (NUVB) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Hattersley Gary
CHIEF SCIENTIFIC OFFICER
Aug 19 '26
Sale
7.09
100,000
709,240
0
GARY HATTERSLEY
Officer
Aug 19 '26
Proposed Sale
6.96
100,000
696,000
0
Sauvage Philippe
Chief Financial Officer
Jul 15 '26
Option Exercise
2.17
40,000
86,800
54,131
Wentworth Kerry
CHIEF REGULATORY OFFICER
Jun 23 '26
Option Exercise
2.93
63,000
184,590
116,000
Wentworth Kerry
CHIEF REGULATORY OFFICER
Jun 23 '26
Sale
6.02
63,000
379,191
53,000
Sauvage Philippe
Chief Financial Officer
Jun 23 '26
Option Exercise
2.17
47,668
103,440
60,341
Sauvage Philippe
Chief Financial Officer
Jun 23 '26
Sale
6.01
47,668
286,370
12,673
STACY MARKEL
Officer
Jun 23 '26
Proposed Sale
5.76
125,000
720,000
0
KERRY WENTWORTH
Officer
Jun 23 '26
Proposed Sale
5.76
63,000
362,880
0
PHILIPPE SAUVAGE
Officer
Jun 23 '26
Proposed Sale
5.76
47,668
274,568
0
$25.50
price up icon 2.59%
$11.71
price up icon 2.49%
$12.75
price up icon 1.84%
$12.09
price up icon 0.25%
$11.41
price up icon 4.44%
$7.29
price up icon 1.25%
Cap:     |  Volume (24h):